Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

Marie Skłodowska-Curie Action · Running

FlexCAT Training program to engage flexible and disordered protein targets for therapeutic development: The oncogene β-catenin as showcase.

Coordinator
Technische Universitaet Wien, Austria
Runs
1 January 2027 to 31 December 2030
Status
Running
EU funding
€4.5m
Total cost
—
Partners
21 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101311592

What the project is doing

In the project's own words, from its summary on CORDIS.

Traditionally, proteins have been categorized into two main structural classes: ordered and disordered. Large parts of the human proteome contain intrinsically disordered regions (IDRs), which are highly flexible and only sometimes adopt a distinct conformation upon interaction with a binding partner. IDRs are fundamental to intracellular signalling and protein interaction networks, particularly transcriptional regulation.

Dysregulation of these processes is strongly associated with diseases including cancer and neurodegenerative disorders. However, targeting IDRs is challenging because of their dynamic nature and the lack of well-defined binding pockets. IDR targets have therefore been largely underrepresented in the pharmaceutical industry and the competencies for characterizing and targeting IDRs are lacking. The aim of the FlexCAT doctoral training network (DN) is to equip a cohort of doctoral candidates (DCs) with unique expertise and knowledge in characterizing and targeting IDRs.

We aim to challenge and complement the limitations of classical small molecule approaches that were primarily developed to target druggable pockets within folded proteins. The DCs will carry out challenging research projects with the aim to assemble, expand, develop and apply novel approaches to understand and exploit disordered targets and IDRs. We will focus on utilizing β-catenin, a central therapeutic target and prime example of an IDR-related drug targeting challenge.

Alongside the individual research projects, the DCs will expand their knowledge and transferrable skills through a structured training program, including secondments and contributions from the non-academic sector. The outcome of the FlexCAT DN will be increased understanding of the role of disordered targets and IDRs, their implications in disease and particularly cancer, while also developing practical strategies for exploring the therapeutic intervention of alternative IDR-related protein targets.

Topics

Who is involved

OrganisationCityCountryRole
Technische Universitaet WienWienAustriaCoordinator
Boehringer Ingelheim Rcv GmbH & Co KgWienAustriaAssociatedpartner
Medizinische Universitat GrazGrazAustriaParticipant
Georg-August-Universitat Gottingen Stiftung Offentlichen RechtsGottingenGermanyParticipant
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbHNeuherbergGermanyParticipant
Julius-Maximilians-Universitat WurzburgWuerzburgGermanyParticipant
Technische Universitaet MuenchenMuenchenGermanyAssociatedpartner
The Hebrew University of JerusalemJerusalemIsraelParticipant
Istituto Europeo Di Oncologia SRLMilanoItalyAssociatedpartner
Universita Degli Studi Di MilanoMilanoItalyParticipant
Universite Du LuxembourgEsch-Sur-AlzetteLuxembourgParticipant
EnzyTag BVNuthNetherlandsAssociatedpartner
Figlinq B.V.AmsterdamNetherlandsAssociatedpartner
Prinses Maxima Centrum Voor Kinderoncologie BVUtrechtNetherlandsParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Stichting Oncode InstituteUtrechtNetherlandsAssociatedpartner
Universiteit UtrechtUtrechtNetherlandsAssociatedpartner
Universiteit Van AmsterdamAmsterdamNetherlandsAssociatedpartner
Direktoratet for Medisinske ProdukterOsloNorwayAssociatedpartner
The University of SussexBrightonUnited KingdomParticipant
Genentech IncSouth San Francisco CaUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI